The endocannabinoid system regulates key biological functions such as neuroprotection, pain modulation, inflammation, and immunomodulation. Cannabis-based therapies have gained attention due to the therapeutic potential of their bioactive compounds, particularly phytocannabinoids like cannabidiol (CBD), which exhibit anti-inflammatory, neuroprotective, and immunomodulatory properties. Mesenchymal stem cells (MSCs) are widely studied for their regenerative and immunomodulatory potential. This study evaluated the effects of priming canine adipose tissue-derived MSCs (cAT-MSCs) with a CBD-rich cannabis extract on cell morphology, viability, neurotrophic factor gene expression, and cytokine gene and protein expression. cAT-MSCs (n = 5) were primed for 24 h and divided into three groups: Control (C, unprimed), D1 (2.25 µM CBD), and D2 (225 nM CBD). No morphological or viability changes were observed. Gene expression analysis showed that groups D1 and D2 exhibited increased HGF expression. D1 also showed increased IDO and decreased BDNF expression. In contrast, no significant changes were observed in GDNF, IL-10, TNF-α, IFN-γ, or PTGES2. Regarding the cytokine profile, GM-CSF, IL-2, and IL-10 were undetectable. Notably, IL-8 and MCP-1 levels were significantly reduced in D1 compared to the control. These findings suggest that CBD priming modulates key regenerative and inflammatory mediators in cAT-MSCs, supporting its potential application in enhancing the efficacy of cell-based therapies.

A Cannabis sativa L. e seus derivados têm se destacado em estudos científicos pelas suas propriedades terapêuticas, especialmente no campo da medicina regenerativa. Nosso projeto investiga os efeitos do extrato full spectrum de CBD em células tronco mesenquimais derivadas do tecido adiposo canino. Os receptores canabinoides são conhecidos por influenciar processos como apoptose, migração celular e a expressão de citocinas inflamatórias e fatores neurotróficos, demonstrando um potencial significativo para aplicações terapêuticas em doenças inflamatórias e degenerativas. Ao investigar esses efeitos, buscamos gerar conhecimento que possa contribuir para o desenvolvimento de novas terapias imunomoduladoras, com impacto direto na medicina veterinária e humana. Investigar o impacto do CBD em células tronco mesenquimais caninas, avaliando a expressão dos receptores CB1 e CB2, e analisar se o CBD influencia a viabilidade e secreção de fatores anti-inflamatórios e neurotróficos, visando otimizar terapias regenerativas. As células tronco mesenquimais foram isoladas de tecido adiposo canino, cultivadas e caracterizadas em laboratório. Em seguida, foram tratadas com extrato full spectrum de CBD nas doses de 2,25 μM e 225 nM. Os ensaios incluíram as análises de viabilidade celular (MTT) e expressão gênica de citocinas inflamatórias (como PTEG2, IDO, IL-10, TNF-α e INF-ɣ) e de fatores neurotróficos (HGF, BDNF e GDNF) por meio da técnica de qtPCR. Também foi avaliada morfologia celular por meio de fotomicrografia. A estimulação in vitro por 24 h das AT-MSCs caninas com o extrato de Cannabis rico em CBD nas doses de 2,25 μM e 225 nM não alterou a morfologia celular, não prejudicou sua viabilidade e não influenciou a expressão gênica da PTGES2, IDO, TNF-α, INF-γ, IL-10, BDNF, GDNF e HGF. Palavras-chave: Terapia celular; Imunomodulação; Fitocanabinoides.

The endocannabinoid system regulates key biological functions such as neuroprotection, pain modulation, inflammation, and immunomodulation. Cannabis-based therapies have gained attention due to the therapeutic potential of their bioactive compounds, particular-ly phytocannabinoids like cannabidiol (CBD), which exhibit anti-inflammatory, neuro-protective, and immunomodulatory properties. Mesenchymal stem cells (MSCs) are widely studied for their regenerative and immunomodulatory potential. This study evaluated the effects of priming canine adipose tissue-derived MSCs (cAT-MSCs) with a CBD-rich can-nabis extract on cell morphology, viability, neurotrophic factor gene expression, and cyto-kine gene and protein expression. cAT-MSCs (n = 5) were primed for 24 hours and divided into three groups: Control (C, unprimed), D1 (2.25 µM CBD), and D2 (225 nM CBD). No morphological or viability changes were observed. Gene expression analysis showed that groups D1 and D2 exhibited increased HGF expression. D1 also showed increased IDO and decreased BDNF expression. In contrast, no significant changes were observed in GDNF, IL-10, TNF-α, IFN-γ, or PTGES2. Regarding the cytokine profile, GM-CSF, IL-2, and IL-10 were undetectable. Notably, IL-8 and MCP-1 levels were significantly reduced in D1 compared to control. These findings suggest that CBD priming modulates key regenerative and inflammatory mediators in cAT-MSCs, supporting its potential application in en-hancing the efficacy of cell-based therapies.